Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?

Published:December 16, 2011DOI:


      Material and Methods

      Within the group of 47 patients treated with peptide receptor radionuclide therapy (PRRT), four patients were chosen: three with inoperable tumors without liver metastases and one with two lesions in the pancreas and metastases.


      In all patients, after PRRT, the changes in the sum of the longest diameters of tumors were between −1% and −21%, resulting in stable disease reported [strict Response Evaluation Criteria in Solid Tumors (RECIST)]. But the measurements of tumor volume and attenuation in computed tomography and the tumor to nontumor ratio in somatostatin receptor scintigraphy resulted in different response assessments.


      The RECIST standard may be not sufficient to properly assess the therapy response in patients with neuroendocrine tumors.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Modlin IM
        • Oberg K
        • Chung DC
        • et al.
        Gastroenteropancreatic neuroendocrine tumors.
        Lancet Oncol. 2008; 9 ([PMID 18780869]): 61-72
        • Oberg K
        • Kvols L
        • Caplin M
        • et al.
        Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
        Ann Oncol. 2004; 15 ([PMID 15151956]): 966-973
        • Kaemmerer D
        • Prasad V
        • Daffner W
        • et al.
        Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.
        World J Gastroenterol. 2009; 15 ([PMID 19998512]): 5867-5870
        • Shimizu T
        • Hirano A
        • Watanabe O
        • et al.
        Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
        Anticancer Res. 2010; 2 ([PMID 20332474]): 581-585
        • Gabriel M
        • Andergassen U
        • Putzer D
        • et al.
        Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.
        Q J Nucl Med Mol Imaging. 2010; 54 ([PMID 20168291]): 92-99
        • Kaltsas GA
        • Besse GM
        • Grossman AB
        The diagnosis and medical management of advanced neuroendocrine tumors.
        Endocr Rev. 2004; 25 ([PMID 15180952]): 458-511
        • Therasse P
        • Arbuck S
        • Eisenhauer E
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors.
        J Natl Cancer Inst. 2000; 92 ([PMID 10655437]): 205-216
        • Eisenhauer E
        • Therasse P
        • Bogaerts J
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45 ([PMID 19097774]): 228-247
        • Stoeltzing O
        • Loss M
        • Huber E
        • et al.
        Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.
        Langenbecks Arch Surg. 2010; 395 ([PMID 19506898]): 185-192
        • Tan EH
        • Tan CH
        Imaging of gastroenteropancreatic neuroendocrine tumors.
        World J Clin Oncol. 2011; 2 ([PMID 21603312]): 28-43
        • Plockinger U
        • Rindi G
        • Arnold R
        • et al.
        Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).
        Neuroendocrinology. 2004; 80 ([PMID 15838182]): 394-424
        • Sowa-Staszczak A
        • Pach D
        • Chrzan R
        • et al.
        Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs).
        Eur J Nucl Med Mol Imaging. 2011; 38 ([PMID: 21559978]): 1669-1674
        • Choi H
        • Charnsangavej C
        • Faria SC
        • et al.
        Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
        J Clin Oncol. 2007; 25 ([PMID 17470865]): 1753-1759
        • Llovet J
        • Di Bisceglie A
        • Bruix J
        • et al.
        Design and endpoints of clinical trials in hepatocellular carcinoma.
        J Natl Cancer Inst. 2008; 100 ([PMID 18477802]): 698-710